• Roche commits to cutting 90% of emissions across its entire value chain by 2045, validated by the Science Based Targets initiative (SBTi).
• The company aims for a 70% reduction in Scope 1 & 2 emissions and a 22.5% cut in Scope 3 emissions by 2029.
• 70% of Roche’s key suppliers must adopt science-based targets to align with sustainability goals.

Swiss pharmaceutical giant Roche announced its long-term and short-term greenhouse gas (GHG) reduction targets, validated by the Science Based Targets initiative (SBTi), aligning with the 1.5°C Paris Agreement goal.

By 2045, Roche aims to achieve net zero emissions across its operations and value chain—covering Scopes 1, 2, and 3—through a 90% absolute reduction, with the remaining 10% offset using permanent carbon removal methods like carbon capture.

Near-term, Roche is targeting a 70% absolute reduction in Scope 1 and 2 emissions by 2029 (based on 2022 levels) and a 22.5% absolute cut in Scope 3 emissions, including fuel & energy, business travel, and product lifecycle impacts. Additionally, the company expects 70% of its suppliers (by emissions) to set science-based targets.

RELATED ARTICLE: Lenovo Commits to Net Zero Emissions by 2050, Validated by Science Based Targets Initiative

Roche is accelerating climate initiatives by transitioning to 100% sustainable electricity by 2025 (up from 86% in 2024), enhancing energy efficiency, and engaging suppliers to embed sustainability throughout its supply chain. Notably, Scope 3 emissions account for roughly 95% of Roche’s total GHG footprint.

Silke Hörnstein, Roche’s Head of Corporate Strategy and Sustainability:
“It is well understood that planetary health and human health are interconnected. The SBTi validation underscores our deep commitment to addressing climate change and enabling a sustainable future for all. We are prioritizing significant reductions across our entire value chain to achieve these targets.”

Follow ESG News on LinkedIn